Get the Stockscreener App
1.95
3.17%
0.06
Grace Therapeutics Inc stock is traded at $1.95, with a volume of 109.29K.
It is up +3.17% in the last 24 hours and down -12.56% over the past month.
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
See More
Previous Close:
$1.89
Open:
$1.91
24h Volume:
109.29K
Relative Volume:
1.27
Market Cap:
$41.02M
Revenue:
Net Income/Loss:
$-7.79M
P/E Ratio:
-4.0608
EPS:
-0.4802
Net Cash Flow:
$-8.94M
1W Performance:
-4.41%
1M Performance:
-12.56%
6M Performance:
-55.28%
1Y Performance:
-37.36%
1-Day Range:
$1.89
$1.97
1-Week Range:
$1.8461
$2.09
52-Week Range:
$1.79
$5.18
Grace Therapeutics Inc Stock (GRCE) Company Profile
Name
Grace Therapeutics Inc
Sector
Industry
Phone
609-322-1602
Address
103 CARNEGIE CENTER, PRINCETON
Compare GRCE vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRCE
Grace Therapeutics Inc
|
1.95 | 41.02M | 0 | -7.79M | -8.94M | -0.4802 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Grace Therapeutics Inc Stock (GRCE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-02-25 | Initiated | TD Cowen | Buy |
| Sep-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-06-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jan-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-29-19 | Initiated | B. Riley FBR | Buy |
| Jul-18-19 | Initiated | Oppenheimer | Outperform |
| Jun-26-19 | Initiated | H.C. Wainwright | Buy |
View All
Grace Therapeutics Inc Stock (GRCE) Latest News
Opaleye management, a 10% owner, buys $123,819 of Grace Therapeutics stock - Investing.com Nigeria
Opaleye management, a 10% owner, buys $123,819 of Grace Therapeutics stock - Investing.com
Form 4 Grace Therapeutics, Inc For: 6 October By Investing.com - Investing.com Nigeria
Form 4 Grace Therapeutics, Inc For: 6 October By Investing.com - Investing.com Canada
Form 4 Grace Therapeutics, Inc For: 6 October By Investing.com - Investing.com UK
Three purchases total 60,490 shares in Grace Therapeutics (GRCE) for Opaleye. - Stock Titan
At $2.09 a share, Opaleye buys 7,849 shares of Grace Therapeutics (GRCE). - Stock Titan
Ownership totals are corrected at Grace Therapeutics (GRCE) after purchases of 9,771 and 5,318 shares. - Stock Titan
Form 4 Grace Therapeutics, Inc For: 27 September By Investing.com - Investing.com Nigeria
Scienture Holdings, Inc. (SCNX) Stock Price & News - Syfe
Form 4 Grace Therapeutics, Inc For: 23 September By Investing.com - Investing.com Canada
Kairos Pharma, Ltd. (KAPA) Stock Price & News - Syfe
Grace Therapeutics director Opaleye Management buys $31,686 in stock - Investing.com
A fund bought 9,771 and 5,318 Grace Therapeutics (GRCE) shares in two purchases at $2.10 each. - Stock Titan
Form 4 Grace Therapeutics, Inc For: 22 September By Investing.com - Investing.com Nigeria
Grace Therapeutics Director A. Brian Davis Awarded 12,200 Stock Options - Kalkine Media
Grace Therapeutics Director Edward Neugeboren Granted Stock Options - Kalkine Media
Grace Therapeutics (GRCE) director gets 12,200 new stock options - Stock Titan
Grace Therapeutics (GRCE) gives director 12,200 stock options with one-year vesting - Stock Titan
Director at Grace Therapeutics (GRCE) awarded 12,200 stock options - Stock Titan
Investors at Grace Therapeutics (GRCE) choose annual say‑on‑pay vote - Stock Titan
Grace Therapeutics (GRCE) 10% holder buys more stock - Stock Titan
CEO Prashant Kohli Buys 100,000 Shares of Grace Therapeutics Inc (GRCE) - GuruFocus
Grace Therapeutics CEO Kohli acquires $214,000 in common stock - Investing.com
Grace Therapeutics CEO Kohli acquires $214,000 in common stock By Investing.com - Investing.com Canada
Grace Therapeutics CEO Kohli acquires $214,000 in common stock By Investing.com - Investing.com India
Grace Therapeutics CEO Kohli acquires $214,000 in common stock By Investing.com - Investing.com UK
Grace Therapeutics CEO Kohli acquires $214,000 in common stock - Investing.com
CEO of Grace Therapeutics (GRCE) adds 100K shares - Stock Titan
Grace Therapeutics CEO Kohli acquires $214,000 in common stock By Investing.com - Investing.com South Africa
Grace Therapeutics (GRCE) Dips 1.0% to $2.08, Holds Above Key SupportPullback Trade - dars.gov.et
Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference - The Manila Times
A drug company CEO's presentation goes online Sept. 11. He'll meet investors in New York. - Stock Titan
Grace Therapeutics (GRCE) awards finance chief options vesting over three years - Stock Titan
Grace Therapeutics (GRCE) grants CEO options at $2.12 - Stock Titan
Grace Therapeutics, Inc. SEC Filing (Sep 1, 2026) - Stock Titan
Grace Therapeutics (GRCE) awards stock options to its chief medical officer - Stock Titan
Grace Therapeutics clears FDA safety hurdles for GTx-104 - scanx.trade
Opaleye Management Inc. Expands Stake in Grace Therapeutics Inc (GRCE) Despite Market Headwinds - GuruFocus
Grace TherapeuticsSelling Stockholders May Resell Up To 4,761,904 Shares Of Common StockSEC Filing - TradingView
Grace (GRCE) Quarterly Results: EPS Lands Above Forecast at the Close; Post-Earnings: The Stock Ends Up 2.80% in the Latest SessionCore Business Growth - vinanet.vn
Grace Therapeutics files prospectus for 4.762m share sale - scanx.trade
Grace Therapeutics Files for Resale of Up to 4.8 Million Shares - finance.yahoo.com
Grace (GRCE) Earnings Reading: EPS Exceeds Its Estimate in Latest Trading; Price Move: Shares Move 2.80% Higher - vinanet.vn
Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest ReadingTech Earnings Analysis - vinanet.vn
Opaleye Management buys $24,206 of Grace Therapeutics stock By Investing.com - Investing.com Canada
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Opaleye Management buys $24,206 of Grace Therapeutics stock By Investing.com - Investing.com UK
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares - Stock Titan
Grace Therapeutics Inc Stock (GRCE) Financials Data
Revenue
Net Income
Cash Flow
EPS
Grace Therapeutics Inc Stock (GRCE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner |
Oct 09 '26 |
Buy |
2.04 |
5,340 |
10,918 |
2,866,074 |
| Opaleye Management Inc. | 10% Owner |
Oct 08 '26 |
Buy |
2.02 |
2,077 |
4,190 |
2,860,734 |
| Opaleye Management Inc. | 10% Owner |
Oct 05 '26 |
Buy |
2.06 |
1,694 |
3,490 |
2,858,657 |
| Opaleye Management Inc. | 10% Owner |
Oct 02 '26 |
Buy |
2.07 |
20,000 |
41,368 |
2,856,963 |
| Opaleye Management Inc. | 10% Owner |
Oct 01 '26 |
Buy |
2.04 |
38,796 |
78,961 |
2,836,963 |
| Opaleye Management Inc. | 10% Owner |
Sep 29 '26 |
Buy |
2.09 |
7,849 |
16,404 |
2,798,167 |
| Opaleye Management Inc. | 10% Owner |
Sep 23 '26 |
Buy |
2.10 |
5,318 |
11,168 |
2,855,318 |
| Opaleye Management Inc. | 10% Owner |
Sep 21 '26 |
Buy |
2.10 |
9,771 |
20,519 |
2,850,000 |
| Opaleye Management Inc. | 10% Owner |
Sep 09 '26 |
Buy |
2.09 |
5,836 |
12,197 |
2,775,229 |
| Kohli Prashant | Chief Executive Officer |
Sep 09 '26 |
Buy |
2.14 |
100,000 |
214,000 |
121,357 |
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):